Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.

Slides:



Advertisements
Similar presentations
Egyptian Guidelines For Management of Chronic Hepatitis B
Advertisements

Treatment appropriate Normal or minimal hepatitis Chronic hepatitis Normal or inactive hepatitis Progressive fibrosis Cirrhosis HCC HBeAg Anti-HBe HBV.
Professor George KK Lau The University of Hong Kong Hong Kong SAR, China HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated.
CORRELATION BETWEEN HBSAG LEVEL AND VIRAL LOAD
Hepatitis web study H EPATITIS W EB S TUDY Therapeutic Agents Used to Treat Hepatitis B Presentation Prepared by: Nina Kim, MD and David Spach, MD Last.
Patrizia FARCI. Hepatitis Delta Virus Hepatitis B surface antigen (HBsAg) HDV RNA genome Hepatitis delta antigen (HDAg) 36 nm From HDV: From HBV: From.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a versus Interferon alfa-2a Phase 3 Treatment Naïve, Chronic HCV Zeuzem S, et al. N Engl J.
Hepatitis web study Hepatitis web study Duration and Dose Finding Peginterferon alfa-2a + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Randomized study.
Coinfection with Hepatitis B and HIV Chia C. Wang Assistant Professor of Medicine AIDS Clinical Conference February 20, 2007.
Robert PERRILLO. 2 nd Paris Hepatitis Conference Why Do I Treat my HBeAg Negative Chronic Hepatitis B Patients with Pegylated Interferon.
3 rd Paris Hepatitis Conference January, 20th 2009 How to optimize the management of my HBeAg negative patients? Pietro Lampertico 1st Gastroenterology.
3rd Paris Hepatitis Conference: Morning Session on HBeAg-Neg CHB WHY DO I TREAT MY PATIENTS WITH PEGYLATED INTERFERON? PEGYLATED INTERFERON?
1 FDA Advisory Meeting Clinical Trial Design – Hepatitis B Treatment Anna S.F. Lok, M.D. University of Michigan Ann Arbor, M I.
1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.
Hepatitis B and Acute Liver Failure Jack Kuritzky, PGY-2 UNC Internal Medicine Morning Report 3/12/10.
1 Roadmap for Management of Patients with Chronic Hepatitis B (CHB) Prof. Xinxin Zhang Rui Jin Hospital Jiao Tong University.
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
George LAU. Hepatitis B e antigen positive patients: Why do I treat my patient with pegylated interferon? 2nd Hepatitis Paris conference George KK Lau,
Hepatitis B Patricia D. Jones, M.D. November 13, 2009.
1. Sustained suppression of HBV replication Decrease in serum HBV DNA to
ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
Treating HBV Infection: Sustained Remission with Immune control Joseph Sung MD, PhD Department of Medicine and Therapeutics Institute of Digestive Diseases.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
Hepatitis B The Basics David Wong University of Toronto March 2005.
SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.
SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.
SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.
HBV Factors and Clinical Outcomes M Omata. Genotypes in China and Japan.
 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.
Date of download: 5/28/2016 From: Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Meta-Analysis.
내과스텝강의 국내 만성B형간염의 현황과 치료 전략.
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.
Maria Buti, MD Professor of Medicine Hospital Universitario Vall d'Hebron Barcelona, Spain Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and.
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
Maria Buti,1 Yoav Lurie,2 Natalia G. Zakharova,3 Natalia P. Blokhina,4 Andrzej Horban,5 Gerlinde Teuber,6 Christoph Sarrazin,6 Ligita Balciuniene,7 Saya.
Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang-Hyub Han, and.
بنام خداوند مهربان. دکتر نرگس نجفی دانشیار دانشگاه.
A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Hepatitis B virus infection in renal transplant recipients
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Treatment of HBV/HCV Coinfection
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
Publication stage: In Press Accepted Manuscript
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Treatment Selection for HBV-Infected Patients With Decompensated.
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.
Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and Cirrhosis
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up  Willem P. Brouwer, Henry Lik-Yuen Chan,
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Volume 67, Issue 2, Pages (August 2017)
How to optimize the management of my HBeAg negative patients?
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Natural history of hepatitis B
Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen–positive chronic.
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Volume 135, Issue 2, Pages (August 2008)
Volume 136, Issue 2, Pages (February 2009)
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China  Y. Zhang,
Ming-Ling Chang, Yun-Fan Liaw  Journal of Hepatology 
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis  Jin Dong Kim, Jong Young Choi, Si Hyun.
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up  Willem P. Brouwer, Henry Lik-Yuen Chan,
Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients  H.-Y. Pan, H.-Y. Pan,
Volume 62, Issue 4, Pages (April 2015)
HEPATITIS B VIRUS ; WHAT`S NEW
Volume 137, Issue 6, Pages (December 2009)
Volume 65, Issue 4, Pages (October 2016)
Presentation transcript:

Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry L.-Y. Chan, Harry L.A. Janssen Response-Guided Peginterferon Therapy in Hepatitis B e Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels R1. 박은지 / Pf. 심재준 Hepatology 2013;58:

Introduction Chronic hepatitis B (CHB) ; One of the leading causes of cirrhosis and hepatocellular carcinoma Peginterferon-alfa (PEG-IFN) ; Suppression of HBV DNA, HBeAg loss, HBsAg clearance → HCC ↓ (BUT) Limited response rates → Clinical application is compromised → Careful selection of patients ; Genotype A or B > C or D Higher ALT Lower HBV DNA HBsAg may predict response to PEG-IFN therapy in CHB → Limited prediction role ~!

Patients - HBeAg-positive CHB patients who were previously enrolled in three separate randomized controlled trials on PEG-IFN therapy (Total N=899) Methods (1) 1. PEG-IFN alfa-2a Phase 3 study (N=542) 2. HBV study (N=221) 3. Neptune study (N=136) PEG-IFN(P) : Lamivudine(L) : PEG-INF + Lamivudine(P+L) 48 wks Respose : 6mo (post Tx) P : P + L 52wks Respose : 6mo P (full dose;180ug/wk) : P (half dose;90ug/wk) 24wk or 48wks Respose : 6mo Inclusion (N=803)Exclusion (N=96) - HBsAg positive for at least 6 mo - HBeAg positive - Elevated ALT X1~10 ULN - HBV DNA levels > 1.0 X 10 5 copies/mL - Coinfection (HCV, hepatitis delta virus, HIV) - Decompensated liver disease - Previous antiviral therapy within 6 mo - Neutropenia - Thrombocytopenia.

Lab measurements : serum HBsAg, HBV DNA, ALT, HBV genotype → Baseline ~ during the treatment (End of Tx) ~ follow-up (6mo post Tx) Response to treatment : HBeAg loss + HBV DNA level <2,000 IU/mL or HBsAg loss Methods (2)

Results (1) Table 1. Characteristics of the Study Cohort Total N=803

Results (2) Fig. 1. Change in serum HBsAg from baseline during treatment and 6 months of off-treatment follow-up across HBV genotypes A through D P < 0.001

Results (3) Fig. 2. Mean change in serum HBsAg from baseline in patients with a response by HBV genotype A through D P < Overall D C B A

Results (4) Fig. 3. Application of the prediction rules based on HBsAg levels at week 12 (A) and 24 (B) and HBsAg declines at weeks 12 (C) and 24 (D) 12 wks HBsAg level 12 wks HBsAg declines 24wks HBsAg declinesHBsAg level

Results (5) Table 2. Observed Response Rates According to HBsAg Level at Week 12 Stratified by HBV Genotype Table 3. According to HBsAg Decline at Week 12

Results (7) Table 4. Performance of Proposed Stopping-Rules at Week 12 And 24 for Response Across the HBV Genotypes in Patients Treated With Peginterferon Monotherapy for 1 Year

Results (8) Fig. 4. Relationship between HBsAg level (in IU/mL) at week 24 of treatment and response 6 months off-treatment.

Conclusion HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB HBV genotype-specific stopping-rules may be considered at week 12 But treatment discontinuation is indicated in all patients with HBsAg >20,000 IU/mL at week 24, irrespective of HBV genotype

Thank you !